Skip to content

TYBR Health

2 viewers · 30d

Total raised

$14.4M

+$14.4M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $14.4M
ROUNDS
1
INVESTORS
12
FOUNDED
N/A
HQ
Houston, TX
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

TYBR Health is a Houston, Texas medical device company founded in 2020 that develops biomaterials to protect healing tissue after surgery. Its lead product, the B3 GEL System, is a flowable extracellular-matrix hydrogel applied at the end of tendon and ligament repair procedures to keep healing tissue from tethering to surrounding structures. The company is a Y Combinator Winter 2022 company and has been backed by MedTech Innovator, the National Institutes of Health, Creative Destruction Lab and JLABS. It has enrolled its first patients in a clinical trial of the B3 GEL System in tendon surgery.

What sets it apart

A naturally derived, brilliant-blue-tinted flowable ECM hydrogel that maintains biomechanical separation during the critical healing window, rather than a physical membrane or barrier film that carries mechanical impingement risk.

Funding history

1 round
EquityJul 9, 2026
Form D
+$14.4M$14.4M total

Latest SEC filings

via EDGAR · CIK 0001835188
Form D · Jul 9, 2026NewView on EDGAR

Products

1 tracked

B3 GEL System

Surgical biomaterial / medical device

A flowable, extracellular-matrix-based protective gel delivered during surgery that coats repaired tendons and adjacent tissue to limit restrictive scar formation and preserve gliding motion during healing.

  • Flowable ECM-based gel that conforms to irregular tissue surfaces
  • Brilliant blue tint for precise visualization during surgical application
  • Maintains biomechanical separation through the critical healing phase
  • Limits restrictive scar formation without the mechanical impingement risk of a solid barrier

Links

WebsiteLinkedInSEC EDGAR filings